WHAT’S NEW?

 

Theravalues Corporation launches VFE17_Theravalues_250
new curcumin product, Theracurmin® Super at

Vitafood Europe
Palexpo, Geneva, Switzerland
May 9-11, 2017
Booth #J166

We’re pleased to announce the launching of new curcumin product, Theracurmin® Super with enhanced bioavailability at one of the most important trades shows focused on health and nutritional supplements and ingredients in Europe.

A seminar on Theracurmin® Super will be provided by Mr. Tadashi Hashimoto, Representative Director and President of Theravalues Corporation on May 9th, Tue. 16:20 – 16:50 at Exhibitor Presentation Theatre.

Session Title: Theracurmin® The Most Advanced Form of Curcumin in Bioavailability
May 9, 2017     16:20 – 16:50      Exhibitor Presentation Theatre

 

New Research Paper on Theracurmin® was published on was published on Nature.com Scientific Reports

December, 2016.
http://www.nature.com/articles/srep39551
Suppression of NLRP3 Inflammasome Activation Ameliorates Chronic Kidney Disease-Induced Cardiac Fibrosis and Diastolic Dysfunction.

 

New Research Paper on Theracurmin® was published on was published on Molecular Nutrition & Food Research

November, 2016.
https://www.ncbi.nlm.nih.gov/pubmed/27990751
Curcumin improves glucose tolerance via stimulation of glucagon-like peptide-1 secretion.

 

New Research Paper on Theracurmin® was published on was published on International Journal of Chronic Obstructive Pulmonary Disease

August, 2016.
https://www.dovepress.com/highly-absorptive-curcumin-reduces-serum-atherosclerotic-low-density-l-peer-reviewed-article-COPD
Highly absorptive curcumin reduces serum atherosclerotic low-density lipoprotein levels in patients with mild COPD.

 

New Research Paper on Theracurmin® was published on Oncology Reports

March, 2016.
https://www.spandidos-publications.com/or/35/3/1463
Theracurmin® efficiently inhibits the growth of human prostate and bladder cancer cells via induction of apoptotic cell death and cell cycle arrest.

 

New short review on EMIQ® was published
on World Biomedical Frontiers

October, 2015.
http://www.biomedfrontiers.org/allergy-2015-16/
Flavonoids for Allergic Diseases: Present Evidence and Future Perspective.

 

Theravalues Corporation establishes
a United States presence at

Supply Side West

Supply Side West
Mandelay Bay, Las Vegas, NV
October 5-9, 2015
Booth #908

We’re pleased to have actively participated as an exhibitor at one of the United State’s most important trades shows focused on health and nutritional supplements and ingredients.

We found that our innovative products, Theracurmin® Highly Bioavailable Curcumin, and EMIQ® (Enzymatically Modified Isoquercitrin) were enthusiastically received by the attendees. We’ve made many valuable new contacts and look forward to interacting with each and every one of them in the future.

At Theravalues Corporation, we’re grateful for this positive response and hope that we will be able to help many more companies include the health benefits of Theracurmin® and EMIQ® in their nutritional supplement products.

 

Theravalues Corporation delivers presentations at

ISNFF 2015 @ Wuxi, China
September 20 -23, 2015
http://www.isnff2015.org/index.php

Oral session 20: Curcumin, Resveratrol and Other Bioactives in Focus
– O111. Theracurmin 2: Short-term effects of highly-bioavailable curcumin for treating early and advanced knee osteoarthritis in human

– O112. Clinical application of highly bioavailable curcumin for patients with cancer

– O113. Theracurmin 3. Highly bioavailable curcumin and its development and clinical applicationNOTE: